Study of Lipid Control in Hyperlipidemic Participants (MK-0653-179)
|ClinicalTrials.gov Identifier: NCT01436253|
Recruitment Status : Completed
First Posted : September 19, 2011
Results First Posted : January 22, 2014
Last Update Posted : April 16, 2015
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.
This study is being done to see whether dietary and medicinal measures compliant with hyperlipidemia treatment guidelines will result in achieving target lipid values and to evaluate the total risk of cardiovascular disease in study participants who have not reached satisfactory lipid levels with their current hypolipemic therapy.
|Condition or disease||Intervention/treatment|
|Dyslipidemia||Behavioral: Lifestyle Changes Drug: Hypolipemics|
|Study Type :||Observational|
|Actual Enrollment :||2196 participants|
|Official Title:||Non-Interventional Study In Hyperlipidemic Patients Who Do Not Reach Satisfactory Lipid Values With Existing Hypolipemic Therapy|
|Study Start Date :||December 2008|
|Primary Completion Date :||February 2013|
|Study Completion Date :||February 2013|
Croatian participants with hyperlipidemia
Participants being treated in a physician's office for hyperlipidemia who have not achieved target lipid levels on their current hypolipemic therapy.
Behavioral: Lifestyle Changes
Diet, increased physical activity, and weight reduction as per European Guidelines on the Management of Hypercholesterolemia accepted by the Croatian Society of Cardiology were encouraged in addition to pharmacological measures at the discretion of the treating physician.Drug: Hypolipemics
Pharmacological measures at the discretion of the treating physician and in accordance with the respective authorized label and European Guidelines on the Management of Hypercholesterolemia accepted by the Croatian Society of Cardiology.
Primary Outcome Measures :
- Percentage of Participants Achieving Target Lipid Values [ Time Frame: Baseline and Month 3 ]Target total cholesterol value was <4.5 mmol/L and target low densisty lipoprotein (LDL) value was <2.5 mmol/L
- Percentage of Participants With Reduced Cardiovascular Risk [ Time Frame: Baseline and Month 3 ]Cardiovascular risk assessment to determine the 10-year risk for developing cardiovascular disease was done using Framingham risk scoring; categories scored are age, high density lipoprotein (HDL) cholesterol value, total cholesterol value, history of cigarette smoking, and systolic blood pressure. The total of all the points for each risk factor is used to assign a percentage of risk for the occurence of cardiovascular disease within 10 years. Total points for men range from -9 to +37 and for women from -8 to +46; >=17 total points for men, and >=25 total points for women indicates a >=30% risk of developing cardiovascular disease.
No Contacts or Locations Provided